|7468449||Phenyl-furan compounds as vitamin D receptor modulators|
The present invention relates to novel, non-secosteroidal, phenyl-furan compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis. ...
|7442793||Peptide deformylase inhibitors|
Novel PDF inhibitors and novel methods for their use are provided. ...
A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 a...
|7388008||Lysine based compounds|
The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for exampl...
|7378448||Diphenylether amide derivatives as opioid receptor antagonists|
A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3′, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mi...
|7378409||Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity|
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
|7351843||Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them|
The present invention relates to furancarbonylguanidine derivatives, a preparation method thereof and a pharmaceutical composition comprising the same. Furancarbonylguanidine derivatives of the present invention inhibit NHE-1 (sodium-hydrogen exchanger isofor...
The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula wherein R, X, R5 and R6 are defined in the specification. The compounds of the invention ...
|7317125||Diacylglycerol acyltransferase inhibitors|
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutica...
Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(═O), S(═O...
This invention relates to novel furancarboxamides of the formula (I) in which R, R1 and m are as defined in the disclosure, to a plurality of processes for preparing these substances and to their use f...
|7153869||Substituted amino acids as erythropoietin mimetics|
This invention relates to a series of substitituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molec...
|7101878||Non-peptide GNRH agents, methods and intermediates for their preparation|
Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorde...
|7041702||Pharmaceutically active compounds and methods of use|
The present invention relates to pharmaceutically acceptable compounds, including acylguanidine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly usefu...
|7019003||Peptide deformylase inhibitors|
Novel PDF inhibitors and novel methods for their use are provided. ...
|7019024||Pharmaceutical for treatment of neurological and neuropsychiatric disorders|
The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof. ...
|6982279||Arylated furan- and thiophenecarboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them|
Compounds of the formulae IA and Ib. in which X, R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(30) and R(31) have the meanings indicated in the claims, are very particularly suitable as novel antiarrhythmic active compou...
|6963010||Hydrophobic polyamine analogs and methods for their use|
The disclosed invention provides new polyamine analogs and derivatives containing a hydrophobic region and a polyamine region as well as methods and compositions for their use. ...
|6960594||Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer|
A novel compound which inhibits certain integrins, particularly αv integrins. Additionally, the novel compound may be used in a method of treating tumors or cancer which comprises administering a pharmaceutically effective amount of the compound to a pat...
|6927290||Production of mixed acid anhydride and amide compound|
There is disclosed an advantageous mixed acid anhydride production method of formula (1): R1C(O)OY(O)n(R2)p (1) wherein R1, R2 and Y denote the same as defined below, n and p ...
|6903132||Non-peptide GnRH agents, pharmaceutical compositions and methods for their use|
Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and ster...
|6891049||Method for producing N-alkoxy-N-alkylamides|
The method for producing N-alkoxy-N-alkylamides of general formula (I): wherein R1 represents C1-10-alkyl, cyclo-C5-7-alkyl, cyclo-C5-7-alkenyl, C2-10-alkenyl, ary...
|6849660||Antimicrobial biaryl compounds|
Provided are antibacterial compounds having Formula I: In such compositions, X is O or S; Y is CH2; n is 0 or 1. One of R1 and R1′ is —C(O)NR5R5′
|6841688||Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone|
Disclosed is a method of preparing an optically pure (R)- or (S)-tetrahydrofuranyl ketone. By such a method, (R)- or (S)-2-tetrahydrofuran amide is converted to (R)- or (S)-2-tetrahydrofuran nitrile through dehydration in the presence of a dehydrating agent and an a...
|6803384||Diaminopropionic acid derivatives|
A compound of formula Id and pharmaceutically acceptable salts and esters thereof, wherein the substituent designations are as provided in the specification. Compounds of the invention are useful for treating reperfusi...
|6790866||Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient|
The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is ...
|6677360||Biphenyl and biphenyl-analogous compounds as integrin antagonists|
The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophyl...
|6673784||Electrophilic ketones for the treatment of herpesvirus infections|
A class of compounds is described which can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula II ##STR1## wherein each of R1, R2, and R3 is independently selected f...
|6646137||Non-peptide GnRH agents|
Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and Z are defined variables: ##STR1## Such compounds and their pharmaceutically accepta...
|6632816||Aromatic derivatives as HIV aspartyl protease inhibitors|
The present invention provides HIV aspartyl protease inhibitors of the formula; ##STR1## and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, wherein R1 may b...
|6596752||Inhibitors of 댔댡 mediated cell adhesion|
The present invention relates to small molecules according to the formula [I]: ##STR1## which are potent inhibitors of 댔ଲ.sub.1 mediated adhesion to either VCAM or CS-1 and which can be used for treating or preventing
A dimethylfurancarboxyanilide compound of the formula (I): ##STR1## wherein R1 and R2 are the same or different and each is hydrogen, (C2 -C6)-alkyl, (C3 -C6)-cycloalkyl, (C3 -C
|6455520||Benzamide derivatives and their use as cytokine inhibitors|
The invention concerns amide derivatives of formula (I) ##STR1## wherein R3 is (1-6C)alkyl or halogeno; m is 0-3, p is 0-2 and q is 0-4; each of R1 and R2 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; R
|6448290||Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient|
The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: ##STR1## (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is --COR1, --CH.db...
|6426355||Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group|
Compounds having the formula: ##STR1## wherein R1 -R5, X and G are described herein and which are useful in the treatment of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Bar...
|6420427||Aminobutyric acid derivatives|
An aminobutyric acid derivative of the formula (I): ##STR1## (wherein all symbols are as defined in the specification) and salt thereof. salt thereof. The compounds of the formula (I) possess an inhibitory activity on matrix metalloproteinase and are usef...
|6407249||Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group|
Compounds of the formula: ##STR1## wherein R1 -R5 are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl...
|6369225||Compounds having activity as inhibitors of cytochrome P450RAI|
Compounds having Formula 8 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. ##STR1##...
Phenylalanine derivatives of formula (1) are described: ##STR1## wherein R is a carboxylic acid or a derivative thereof; L1 is a linker atom or group; Het is an optionally substituted heteroaromatic group; and the salts, solvates, hydrates and N-oxides t...
|6319930||Substituted dimeric compounds|
The invention relates to compounds of formula (I): A--G1 --Cy--G2 --Cy--G3 --B (I) wherein: A represents NR1 C(Q)R2, C(Q)NR2 R3 or NR1 C(Q)NR2 R3, B repre...